Literature DB >> 30537472

Pep-1&borneol-Bifunctionalized Carmustine-Loaded Micelles Enhance Anti-Glioma Efficacy Through Tumor-Targeting and BBB-Penetrating.

Xiaoyuan Guo1, Guojian Wu1, Hong Wang1, Lukui Chen2.   

Abstract

Tumor-targeting and blood-brain barrier (BBB)-penetrating are highly desirable for the treatment of glioma. In this study, we developed Pep-1&borneol-bifunctionalized carmustine-loaded micelles (Pep-1/Bor/CMS-M) capable of targeting interleukin-13 receptor-overexpressed glioma and penetrating the brain microvascular endothelial cells-associated physiologic barriers. Pep-1/Bor/CMS-M were nearly spherical particles with a diameter of 32.6 ± 1.1 nm and zeta potential of -21.3 ± 3.1 mV. Carmustine (CMS) released from Pep-1/Bor/CMS-M in pH 7.4 was significantly faster than in acidic environments. In human glioma BT325 cellular studies, Pep-1/Bor/CMS-M remarkably increased the cytotoxicity, notably improved the internalization, and effectively induced the cell apoptosis. Likewise, in human brain microvascular endothelial cells, Pep-1/Bor/CMS-M obviously promoted the cellular uptake, rapidly decreased the transepithelial electrical resistance, and thereby enhanced the ability of penetration. In orthotopic Luc-BT325 glioma tumor-bearing nude mouse models, the stronger fluorescence signal and longer retention were observed in brain tissues compared with other controls, after single administration of DiD-labeled Pep-1/Bor/M (DiD/Pep-1/Bor/M). Importantly, Pep-1/Bor/CMS-M displayed the strongest inhibition of tumor growth, the longest survival period, and low systemic toxicity in treating orthotopic glioma tumor-bearing nude mice. Simultaneous functionalization of Pep-1 and borneol offers a novel strategy for designing CMS-based nanomedicine and precisely treating glioma.
Copyright © 2019 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BBB; IL-13 receptor; borneol; brain targeting; carmustine-loaded micelle

Mesh:

Substances:

Year:  2018        PMID: 30537472     DOI: 10.1016/j.xphs.2018.11.046

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  5 in total

Review 1.  Borneol: a Promising Monoterpenoid in Enhancing Drug Delivery Across Various Physiological Barriers.

Authors:  Madhur Kulkarni; Niserga Sawant; Anjali Kolapkar; Aishwarya Huprikar; Namita Desai
Journal:  AAPS PharmSciTech       Date:  2021-04-28       Impact factor: 3.246

2.  Enhanced Anti-Glioma Efficacy by Borneol Combined With CGKRK-Modified Paclitaxel Self-Assembled Redox-Sensitive Nanoparticles.

Authors:  Lingyan Lv; Xinrui Li; Wei Qian; Shennan Li; Yan Jiang; Yaokun Xiong; Jianpei Xu; Wei Lv; Xiaoyan Liu; Yun Chen; Yulin Tang; Hongliang Xin
Journal:  Front Pharmacol       Date:  2020-04-30       Impact factor: 5.810

Review 3.  Recent Progress on the Synergistic Antitumor Effect of a Borneol-Modified Nanocarrier Drug Delivery System.

Authors:  Jinxiu Li; Qian Xie; Rong Ma; Yong Li; Jianmei Yuan; Mihong Ren; Hongyan Li; Jiajun Wang; Danni Lu; Zhuo Xu; Jian Wang
Journal:  Front Med (Lausanne)       Date:  2021-11-25

Review 4.  Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?

Authors:  Daniel Ruiz-Molina; Xiaoman Mao; Paula Alfonso-Triguero; Julia Lorenzo; Jordi Bruna; Victor J Yuste; Ana Paula Candiota; Fernando Novio
Journal:  Cancers (Basel)       Date:  2022-10-10       Impact factor: 6.575

Review 5.  Blood-Brain Barrier Modulation to Improve Glioma Drug Delivery.

Authors:  Huilong Luo; Eric V Shusta
Journal:  Pharmaceutics       Date:  2020-11-12       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.